Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study

Diana Bonderman, Stefano Ghio, Stephan B. Felix, Hossein Ardeschir Ghofrani, Evangelos Michelakis, Veselin Mitrovic, Ronald J. Oudiz, Francis Boateng, Andrea Viviana Scalise, Lothar Roessig, Marc J. Semigran

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study'. Together they form a unique fingerprint.

Medicine & Life Sciences